Spectrum of genotype and clinical manifestations in cerebral cavernous malformations

Judith Gault1, Stephan Sain, Ling-Jia Hu

  • 1Department of Neurosurgery, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262, USA. Judith.Gault@uchsc.edu

Neurosurgery
|February 6, 2007
PubMed

Insights

Genetic mutations in CCM1 may lead to less severe cerebral cavernous malformations (CCMs) and related symptoms like hemorrhage. However, other genetic factors also influence CCM disease severity.

Area of Science:

  • Neurology
  • Genetics
  • Vascular Biology

Background:

  • Cerebral cavernous malformations (CCMs) are vascular anomalies increasing risk for stroke and epilepsy.
  • CCMs can be sporadic or inherited, with three known causative genes.
  • Significant variability exists in CCM clinical presentations.

Purpose of the Study:

  • To investigate genetic heterogeneity in CCMs.
  • To test the hypothesis that different genes contribute to CCM variability.
  • To correlate CCM gene mutations with clinical manifestations and lesion characteristics.

Main Methods:

  • Prospective enrollment of CCM cases.
  • Screening for CCM1, CCM2, and CCM3 gene mutations in familial and sporadic cases.
  • Association analysis of mutations with clinical outcomes and lesion features in 41 symptomatic familial cases.

Main Results:

  • CCM1 mutations identified in 34/50 familial cases, but not in sporadic cases.
  • CCM2 or CCM3 mutations found in 3/10 families lacking CCM1 mutations.
  • CCM1-mutated familial cases showed high variability in presentation, with fewer experiencing hemorrhage compared to other familial cases, independent of lesion characteristics.

Conclusions:

  • Germline CCM1 mutations are associated with potentially less severe clinical manifestations in familial CCM disease.
  • Factors beyond CCM1 mutations contribute to the overall clinical picture of CCMs.
  • Further research is needed to elucidate the full spectrum of genetic influences on CCM pathogenesis and severity.
Abstract

Related Concept Videos

Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Genetic Lingo01:11

Genetic Lingo

Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...